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Background:  It has been demonstrated that inflammatory resposes appeared shortly after pulmonary vein isolation (PVI), and that those 
responses were closely associated with recurrent atrial fibrillation (AF) occurring within initial 3 days after the procedure (immediate AF recurrences). 
Therefore, non-steroidal anti-inflammatory drug (NSAID), loxoprofen may negate immediate AF recurrences by preventing post-ablation inflammatory 
responces. However, no studies have examined the relation between NSAID administration and AF recurrences after PVI.
Methods:  Fourty patients with AF were randomized to receive either loxoprofen (loxoprofen-group, n=20) or matched with a placebo (placebo-
group, n=20). In the loxoprofen-group, oral loxoprofen (120mg/day) was administered for 7 days after the PVI. The body temperature (BT) was 
measured before and consecutively on the first 3 days after the ablation, and monitor electrocardiography had been recorded for 3 days on 
admission.
Results:  Mean baseline characteristics were not different between the loxoprofen-group and the placebo-group. The prevalence of immediate AF 
recurrences was lower in the loxoprofen-group (10%) than in the placebo-group (40%, p<0.05). The rise in the BT from baseline during the initial 3 
days after the ablation were lower in the loxoprofen-group (0.3±0.3°C) than placebo-group (1.1±0.5°C, p<0.01). The AF free-rate at 3 months post-
abaltion was not different between loxoprofen-group (85%) and placebo-group (75%, ns).
Conclusions:  The transient use of loxoprofen shortly after PVI ablation can be effective and safe for preventing immediate AF recurrences.
